Short-term efficacy of temperature-based radiofrequency ablation of small renal tumors

Edward D. Matsumoto, D. Brooke Johnson, Kenneth Ogan, Clayton K Trimmer, Arthur I Sagalowsky, Vitaly Margulis, Jeffrey A Cadeddu

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Objectives. To present our experience using radiofrequency ablation (RFA) for the treatment of small renal tumors. Our objective was to assess the short-term (1 to 3 years) oncologic efficacy of RFA. Methods. Consecutive renal tumors treated since May 2001 with a minimal follow-up of 6 months were included. Patients were treated with a temperature-based radiofrequency generator and were followed up with serial imaging at 6 weeks, 3 and 6 months, and every 6 months thereafter. Results. A total of 109 small renal tumors (91 patients) were treated with computed tomography-guided percutaneous RFA (n = 63) or laparoscopic RFA (n = 46). The mean tumor size was 2.4 cm (range 0.8 to 4.7). The initial ablation was successful in 107 (98%) of 109 tumors. The two incomplete ablations were successfully re-ablated. Of the 60 patients with at least 1 year of follow-up, 60% had biopsy proven renal cell carcinoma (an additional 24% had no tissue diagnosis). In this group, one local recurrence (1.7%) was detected during a mean follow-up of 19.4 months (range 12 to 33), and in those with known renal cell carcinoma, none had evidence of distant progression (0%). The local recurrence was successfully re-ablated such that all 109 cases had no clinical or radiographic evidence of disease at last follow-up. Three patients died of causes unrelated to cancer. Conclusions. The results of our study have shown that in the short term, RFA appears to be a reasonable therapeutic nephron-sparing approach for treating select patients with small renal tumors. The cancer control appears adequate to date, but longer follow-up is necessary before widespread application.

Original languageEnglish (US)
Pages (from-to)877-881
Number of pages5
JournalUrology
Volume65
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Kidney
Temperature
Neoplasms
Renal Cell Carcinoma
Recurrence
Nephrons
Tomography
Biopsy
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Short-term efficacy of temperature-based radiofrequency ablation of small renal tumors. / Matsumoto, Edward D.; Johnson, D. Brooke; Ogan, Kenneth; Trimmer, Clayton K; Sagalowsky, Arthur I; Margulis, Vitaly; Cadeddu, Jeffrey A.

In: Urology, Vol. 65, No. 5, 05.2005, p. 877-881.

Research output: Contribution to journalArticle

@article{89b3a521e3044202aaafb5fecd7d2bad,
title = "Short-term efficacy of temperature-based radiofrequency ablation of small renal tumors",
abstract = "Objectives. To present our experience using radiofrequency ablation (RFA) for the treatment of small renal tumors. Our objective was to assess the short-term (1 to 3 years) oncologic efficacy of RFA. Methods. Consecutive renal tumors treated since May 2001 with a minimal follow-up of 6 months were included. Patients were treated with a temperature-based radiofrequency generator and were followed up with serial imaging at 6 weeks, 3 and 6 months, and every 6 months thereafter. Results. A total of 109 small renal tumors (91 patients) were treated with computed tomography-guided percutaneous RFA (n = 63) or laparoscopic RFA (n = 46). The mean tumor size was 2.4 cm (range 0.8 to 4.7). The initial ablation was successful in 107 (98{\%}) of 109 tumors. The two incomplete ablations were successfully re-ablated. Of the 60 patients with at least 1 year of follow-up, 60{\%} had biopsy proven renal cell carcinoma (an additional 24{\%} had no tissue diagnosis). In this group, one local recurrence (1.7{\%}) was detected during a mean follow-up of 19.4 months (range 12 to 33), and in those with known renal cell carcinoma, none had evidence of distant progression (0{\%}). The local recurrence was successfully re-ablated such that all 109 cases had no clinical or radiographic evidence of disease at last follow-up. Three patients died of causes unrelated to cancer. Conclusions. The results of our study have shown that in the short term, RFA appears to be a reasonable therapeutic nephron-sparing approach for treating select patients with small renal tumors. The cancer control appears adequate to date, but longer follow-up is necessary before widespread application.",
author = "Matsumoto, {Edward D.} and Johnson, {D. Brooke} and Kenneth Ogan and Trimmer, {Clayton K} and Sagalowsky, {Arthur I} and Vitaly Margulis and Cadeddu, {Jeffrey A}",
year = "2005",
month = "5",
doi = "10.1016/j.urology.2004.12.011",
language = "English (US)",
volume = "65",
pages = "877--881",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Short-term efficacy of temperature-based radiofrequency ablation of small renal tumors

AU - Matsumoto, Edward D.

AU - Johnson, D. Brooke

AU - Ogan, Kenneth

AU - Trimmer, Clayton K

AU - Sagalowsky, Arthur I

AU - Margulis, Vitaly

AU - Cadeddu, Jeffrey A

PY - 2005/5

Y1 - 2005/5

N2 - Objectives. To present our experience using radiofrequency ablation (RFA) for the treatment of small renal tumors. Our objective was to assess the short-term (1 to 3 years) oncologic efficacy of RFA. Methods. Consecutive renal tumors treated since May 2001 with a minimal follow-up of 6 months were included. Patients were treated with a temperature-based radiofrequency generator and were followed up with serial imaging at 6 weeks, 3 and 6 months, and every 6 months thereafter. Results. A total of 109 small renal tumors (91 patients) were treated with computed tomography-guided percutaneous RFA (n = 63) or laparoscopic RFA (n = 46). The mean tumor size was 2.4 cm (range 0.8 to 4.7). The initial ablation was successful in 107 (98%) of 109 tumors. The two incomplete ablations were successfully re-ablated. Of the 60 patients with at least 1 year of follow-up, 60% had biopsy proven renal cell carcinoma (an additional 24% had no tissue diagnosis). In this group, one local recurrence (1.7%) was detected during a mean follow-up of 19.4 months (range 12 to 33), and in those with known renal cell carcinoma, none had evidence of distant progression (0%). The local recurrence was successfully re-ablated such that all 109 cases had no clinical or radiographic evidence of disease at last follow-up. Three patients died of causes unrelated to cancer. Conclusions. The results of our study have shown that in the short term, RFA appears to be a reasonable therapeutic nephron-sparing approach for treating select patients with small renal tumors. The cancer control appears adequate to date, but longer follow-up is necessary before widespread application.

AB - Objectives. To present our experience using radiofrequency ablation (RFA) for the treatment of small renal tumors. Our objective was to assess the short-term (1 to 3 years) oncologic efficacy of RFA. Methods. Consecutive renal tumors treated since May 2001 with a minimal follow-up of 6 months were included. Patients were treated with a temperature-based radiofrequency generator and were followed up with serial imaging at 6 weeks, 3 and 6 months, and every 6 months thereafter. Results. A total of 109 small renal tumors (91 patients) were treated with computed tomography-guided percutaneous RFA (n = 63) or laparoscopic RFA (n = 46). The mean tumor size was 2.4 cm (range 0.8 to 4.7). The initial ablation was successful in 107 (98%) of 109 tumors. The two incomplete ablations were successfully re-ablated. Of the 60 patients with at least 1 year of follow-up, 60% had biopsy proven renal cell carcinoma (an additional 24% had no tissue diagnosis). In this group, one local recurrence (1.7%) was detected during a mean follow-up of 19.4 months (range 12 to 33), and in those with known renal cell carcinoma, none had evidence of distant progression (0%). The local recurrence was successfully re-ablated such that all 109 cases had no clinical or radiographic evidence of disease at last follow-up. Three patients died of causes unrelated to cancer. Conclusions. The results of our study have shown that in the short term, RFA appears to be a reasonable therapeutic nephron-sparing approach for treating select patients with small renal tumors. The cancer control appears adequate to date, but longer follow-up is necessary before widespread application.

UR - http://www.scopus.com/inward/record.url?scp=18844423786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844423786&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2004.12.011

DO - 10.1016/j.urology.2004.12.011

M3 - Article

VL - 65

SP - 877

EP - 881

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -